Skip to main content
Egetis Therapeutics logo

Egetis Therapeutics — Investor Relations & Filings

Ticker · EGTX ISIN · SE0003815604 LEI · 549300RZCKGWRUBPMY22 ST Manufacturing
Open in API
Filings indexed 282 across all filing types
Latest filing 2026-04-30 Regulatory Filings
Country SE Sweden
Listing ST EGTX

About Egetis Therapeutics

https://www.egetis.com/

Egetis Therapeutics is an innovative and integrated pharmaceutical company focused on developing and commercializing treatments for serious and rare diseases with significant unmet medical needs. The company's strategy centers on advancing drug candidates through late-stage clinical development to market approval. Its primary asset, Emcitate (tiratricol), is a first-in-class drug candidate in late-stage development for the treatment of Monocarboxylate Transporter 8 (MCT8) deficiency, a rare congenital disorder of thyroid hormone transport.

Recent filings

Filing Released Lang Actions
Ändring av antalet aktier och röster i Egetis Therapeutics
Regulatory Filings
2026-04-30 English
Change in the number of shares and votes in Egetis Therapeutics
Regulatory Filings
2026-04-30 English
Interim / Quarterly Report 2026
Interim / Quarterly Report Classification · 95% confidence The document is titled “Delårsrapport januari–mars 2026” and contains detailed narrative from the CEO, comprehensive financial statements for the first quarter (sales, cash flow, balance sheet metrics), tables comparing the period to prior periods, and substantive analysis of business developments. It is clearly a standalone interim (quarterly) report, not merely an announcement or presentation. Therefore, it fits the definition of an Interim/Quarterly Report. Q1 2026
2026-04-29 Swedish
Interim / Quarterly Report 2026
Interim / Quarterly Report Classification · 95% confidence The document is clearly labeled as an “Interim report January–March 2026” and contains comprehensive quarterly financial statements, narrative from the CEO, detailed financial tables for the period, and outlook commentary. It is not merely an earnings release highlighting key metrics, nor is it an announcement of a report; it is the full interim/quarterly financial report itself. Thus, it falls under the Interim / Quarterly Report category (IR). Q1 2026
2026-04-29 English
Egetis Therapeutics har framgångsrikt genomfört en riktad nyemission uppgående till 350 miljoner kronor (cirka 38 miljoner dollar)
Share Issue/Capital Change Classification · 94% confidence The document is a press release announcing a directed new share issue (riktad nyemission) of 66,666,667 shares to raise SEK 350 million, including detailed terms, advisors, dilution effects, and usage of proceeds. This is a capital‐raising share issuance and thus classified as a Share Issue/Capital Change announcement (SHA).
2026-04-21 Swedish
Egetis Therapeutics has successfully carried out a directed share issue amounting to SEK 350 million (approximately USD 38 million)
Share Issue/Capital Change Classification · 92% confidence The document is a press release announcing the terms and details of a directed share issue (number of shares to be issued, subscription price, proceeds, dilution, use of proceeds, lock-up terms, etc.). This falls squarely under announcements of new share issues and other capital changes. Therefore, it should be classified as Share Issue/Capital Change (Code: SHA).
2026-04-21 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.